8 completed. 8 Phase 1.
By phase and status
Follow HCV: new trials by email Literature Review of HCV trials Research Report on HCV
Trials (filtered) newest first · largest first
All 8 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
Danoprevir, Ritonavir, Ravidasvir - HCV | Phase 1 | Completed | 18 | 2017-08-08 | 2018-01-17 |
TD-6450 MAD Study in HCV Infected Subjects
TD-6450, Placebo - Hepatitis C, HCV | Phase 1 | Completed | 47 | 2014-05-01 | 2021-01-19 |
VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer
Efavirenz; Tenofovir disoproxil fumarate; Telaprevir - Hepatitis C, HCV | Phase 1 | Completed | 20 | 2009-02-01 | 2010-12-17 |
Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects
[14C]-PF-00868554 - HCV | Phase 1 | Completed | 7 | 2009-01-01 | 2009-03-09 |
TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers
TMC435350 - HCV | Phase 1 | Completed | 30 | 2008-08-01 | 2010-04-28 |
TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule
TMC435350 - Hepatitis C, HCV | Phase 1 | Completed | 24 | 2008-07-01 | 2010-04-28 |
TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.
TMC435350, Rifampin, TMC435350+rifampin - Hepatitis C, HCV | Phase 1 | Completed | 21 | 2008-06-01 | 2013-04-18 |
An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals
Albinterferon, Ribavirin, Albuferon - HIV Infections, HCV | Phase 1 | Completed | 41 | 2007-06-18 | 2017-07-02 |
Narrower conditions
Hepatitis C (6) · HIV Infections (2) · Acquired Immunodeficiency Syndrome (1) · Fibrosis (1) · Tuberculosis (1)
Broader conditions
Blood-Borne Infections (6) · Communicable Diseases (6) · Digestive System Diseases (6) · Flaviviridae Infections (6) · Hepatitis (6) · Hepatitis, Viral, Human (6) · Infections (6) · Liver Diseases (6) · RNA Virus Infections (6) · Virus Diseases (6) · Genital Diseases (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Lentivirus Infections (2) · Retroviridae Infections (2)
Interventions
Simeprevir (3) · Ribavirin (1) · Rifampin (1) · Ritonavir (1) · Tenofovir (1) · albinterferon alfa-2b (1) · albuferon (1) · danoprevir (1) · efavirenz (1) · ravidasvir (1) · telaprevir (1)
Sponsors
Tibotec Pharmaceuticals, Ireland (3) · Ascletis Pharmaceuticals Co., Ltd. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Pfizer (1) · Theravance Biopharma (1) · Tibotec BVBA (1)
Countries
United States (3) · China (1)
Results publications
PMID 34252301